RBC Capital analyst George Hill says this week’s Q3 earnings for Walgreens Boots Alliance may disappoint sell-side consensus of $1.48 and the buy-side expectations of a modest beat due to the recent macro softness in Rx trends. Hill cites the changes in the Medicare Part D preferred networks program as the “key negative” for script growth, though he also expects investors to focus on the company’s “go-forward strategy” within the consolidating healthcare-pharma services industry. The analyst keeps his Outperform rating and $88 price target on Walgreens.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.